title: Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model.
abstract: Tumor hypoxia is relevant for tumor growth, metabolism and epithelial-to-mesenchymal transition (EMT). We report that hyperbaric oxygen (HBO) treatment induced mesenchymal-to-epithelial transition (MET) in a dimethyl-alpha-benzantracene induced mammary rat adenocarcinoma model, and the MET was associated with extensive coordinated gene expression changes and less aggressive tumors. One group of tumor bearing rats was exposed to HBO (2 bar, pO(2) = 2 bar, 4 exposures à 90 minutes), whereas the control group was housed under normal atmosphere (1 bar, pO(2) = 0.2 bar). Treatment effects were determined by assessment of tumor growth, tumor vascularisation, tumor cell proliferation, cell death, collagen fibrils and gene expression profile. Tumor growth was significantly reduced (approximately 16%) after HBO treatment compared to day 1 levels, whereas control tumors increased almost 100% in volume. Significant decreases in tumor cell proliferation, tumor blood vessels and collagen fibrils, together with an increase in cell death, are consistent with tumor growth reduction and tumor stroma influence after hyperoxic treatment. Gene expression profiling showed that HBO induced MET. In conclusion, hyperoxia induced MET with coordinated expression of gene modules involved in cell junctions and attachments together with a shift towards non-tumorigenic metabolism. This leads to more differentiated and less aggressive tumors, and indicates that oxygen per se might be an important factor in the "switches" of EMT and MET in vivo. HBO treatment also attenuated tumor growth and changed tumor stroma, by targeting the vascular system, having anti-proliferative and pro-apoptotic effects.
authors.affiliation: Department of Biomedicine, University of Bergen, Bergen, Norway.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Moen
authors.forename: Anne Margrete
authors.initials: AM
authors.lastname: Øyan
authors.forename: Karl-Henning
authors.initials: KH
authors.lastname: Kalland
authors.forename: Karl Johan
authors.initials: KJ
authors.lastname: Tronstad
authors.forename: Lars Andreas
authors.initials: LA
authors.lastname: Akslen
authors.forename: Martha
authors.initials: M
authors.lastname: Chekenya
authors.forename: Per Øystein
authors.initials: PØ
authors.lastname: Sakariassen
authors.forename: Rolf Kåre
authors.initials: RK
authors.lastname: Reed
authors.forename: Linda Elin Birkhaug
authors.initials: LE
authors.lastname: Stuhr
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000818:Animals; D004847:Epithelial Cells / Q000166:cytology*; D005260:Female; D018496:Hyperoxia / Q000188:drug therapy*; D007150:Immunohistochemistry; D008648:Mesoderm / Q000166:cytology*; D008954:Models, Biological; D051381:Rats; D017207:Rats, Sprague-Dawley